According to Bloomberg, Duke University and Allergan convinced a District of New Jersey judge to strip antitrust counterclaims from their lawsuit accusing Akorn of infringing a patent on the eyelash-loss drug Latisse.
The suit claims Akorn’s generic version of Latisse infringes on one of the many patents on it. It’s the fourth Latisse infringement case filed against Akorn by Duke, the patent holder, and Allergan, which is licensed to sell the drug, in the US District Court for the District of New Jersey.
The prior cases culminated in rulings barring Allergan from reasserting patents that were too similar to those previously rejected, but Duke and Allergan argue that the patent in question here covers methods of use, not chemical compounds.
Akorn sought invalidation of the patent, a declaration it wasn’t infringed, or a ruling that it was too similar to the other rejected Latisse patents, and it filed multiple antitrust claims.
Full Content: Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Health Care Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
NY AG Joins Suit Challenging NCAA’s Restrictions on Student Athlete NIL Rights
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI